The Clinical Development of Thalidomide as an Angiogenesis Inhibitor Therapy for Prostate Cancer
Final addendum rept. 1 Oct 2005-30 Sep 2006
M D ANDERSON CANCER CENTER HOUSTON TX
Pagination or Media Count:
Significant progress has been made in the understanding of key factors that regulate the cell-cell interaction in the context of the microenvironment of prostate cancer. This includes technical advances in getting information from small amounts of tissue to forward understanding of the molecular determinants of progression. We have developed tissue micro arrays TMAs, and stained them for candidate factors implicated in stromal epithelial interaction and have demonstrated that they are expressed in the context of Thalidomide treated patients. This information will be used to compare these results to the expression patterns in similar prostate cancers not exposed to Thalidomide. We are requesting a no-cost extension of 6 months to allow completion of the planned studies. A formal letter will be sent separately.
- Medicine and Medical Research